Legal & General Group Plc Boosts Stake in Theravance Biopharma Inc (NASDAQ:TBPH)

Legal & General Group Plc raised its position in Theravance Biopharma Inc (NASDAQ:TBPH) by 36.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 33,988 shares of the biopharmaceutical company’s stock after buying an additional 9,048 shares during the period. Legal & General Group Plc owned 0.05% of Theravance Biopharma worth $785,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of TBPH. BlackRock Inc. increased its stake in Theravance Biopharma by 129.3% in the 1st quarter. BlackRock Inc. now owns 8,780,790 shares of the biopharmaceutical company’s stock valued at $202,923,000 after buying an additional 4,951,711 shares during the last quarter. Norges Bank purchased a new stake in shares of Theravance Biopharma during the 4th quarter worth approximately $27,847,000. Federated Hermes Inc. increased its stake in shares of Theravance Biopharma by 10,024,250.0% during the 1st quarter. Federated Hermes Inc. now owns 400,974 shares of the biopharmaceutical company’s stock worth $9,267,000 after purchasing an additional 400,970 shares during the last quarter. Chescapmanager LLC increased its stake in shares of Theravance Biopharma by 37.7% during the 4th quarter. Chescapmanager LLC now owns 949,006 shares of the biopharmaceutical company’s stock worth $24,570,000 after purchasing an additional 259,722 shares during the last quarter. Finally, Newtyn Management LLC increased its stake in shares of Theravance Biopharma by 172.1% during the 4th quarter. Newtyn Management LLC now owns 173,300 shares of the biopharmaceutical company’s stock worth $4,487,000 after purchasing an additional 109,619 shares during the last quarter. Hedge funds and other institutional investors own 88.47% of the company’s stock.

TBPH opened at $20.64 on Wednesday. The company has a 50 day moving average of $25.20 and a 200 day moving average of $25.32. The company has a market cap of $1.33 billion, a PE ratio of -4.76 and a beta of 1.47. Theravance Biopharma Inc has a 12 month low of $15.72 and a 12 month high of $31.54.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.07) by ($0.33). The business had revenue of $19.86 million for the quarter, compared to analysts’ expectations of $18.02 million. As a group, equities analysts anticipate that Theravance Biopharma Inc will post -3.88 earnings per share for the current year.

Several equities research analysts have recently issued reports on TBPH shares. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of Theravance Biopharma in a research note on Thursday, May 7th. Cowen started coverage on shares of Theravance Biopharma in a research note on Wednesday, May 13th. They set an “outperform” rating and a $42.00 price target for the company. ValuEngine upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. Zacks Investment Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating and set a $34.00 price objective for the company. in a report on Tuesday, May 12th. Finally, BidaskClub downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, June 20th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $35.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

See Also: Why is a lock-up period needed for an IPO?

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.